Initiating Process Development by Introducing CDC Technology
Injectable Vaccine Expected to Address Low Efficacy of Oral Vaccines

SK Bioscience is collaborating with global health organizations to develop a rotavirus vaccine.


On June 9, SK Bioscience announced that it has signed a license agreement with the U.S. Centers for Disease Control and Prevention (CDC) for the development of an injectable rotavirus vaccine. Under this agreement, SK Bioscience will acquire the technology for the injectable rotavirus vaccine candidate owned by the CDC and proceed with process development to improve productivity. If the process development is successfully completed, the company will move forward with subsequent clinical trials, regulatory approvals, and commercialization.

SK Bioscience Incheon Songdo Headquarters exterior view. SK Bioscience

SK Bioscience Incheon Songdo Headquarters exterior view. SK Bioscience

View original image

The CDC has developed the technology for an injectable inactivated rotavirus vaccine and has been conducting Phase 1 clinical trials. SK Bioscience plans to rapidly introduce this technology into Korea and establish a manufacturing process that can simultaneously enhance efficacy and reduce costs, ultimately advancing through the clinical and commercialization stages. Research funding for process development will be jointly invested by global foundations. Last year, SK Bioscience signed an agreement with the Right Foundation to support research and development costs for the process of this rotavirus vaccine.


Rotavirus is a major infectious disease that causes severe diarrhea and dehydration in children under the age of five. In advanced countries, the introduction of vaccines has significantly reduced infection rates, resulting in 99% of global deaths now occurring in low- and middle-income countries. Currently available oral vaccines demonstrate less than 50% efficacy in these regions due to poor environmental factors and vulnerable nutritional status. As a result, low- and middle-income countries are expecting higher efficacy and improved vaccination rates and accessibility through the development of injectable vaccines.


According to market research firm Business Research Insights, the global rotavirus vaccine market is projected to grow from approximately $8.12 billion (about 11.2 trillion won) in 2024 to about $13.9 billion (about 19.18 trillion won) by 2033.



Jae-yong Ahn, CEO of SK Bioscience, stated, "With the support of the Right Foundation, we are committed to developing innovative vaccines to improve the health of children in low- and middle-income countries and fulfilling our responsibility as a company leading a paradigm shift in global health."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing